Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Equity Ratio (2017 - 2025)

Historic Equity Ratio for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 0.92.

  • Protagonist Therapeutics' Equity Ratio rose 442.43% to 0.92 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92, marking a year-over-year increase of 442.43%. This contributed to the annual value of 0.91 for FY2024, which is 359.32% down from last year.
  • As of Q3 2025, Protagonist Therapeutics' Equity Ratio stood at 0.92, which was up 442.43% from 0.93 recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Equity Ratio high stood at 0.94 for Q4 2023, and its period low was 0.86 during Q4 2021.
  • Over the past 5 years, Protagonist Therapeutics' median Equity Ratio value was 0.88 (recorded in 2021), while the average stood at 0.89.
  • In the last 5 years, Protagonist Therapeutics' Equity Ratio surged by 8729.3% in 2021 and then tumbled by 402.05% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Equity Ratio (Quarter) stood at 0.86 in 2021, then rose by 0.78% to 0.87 in 2022, then increased by 8.16% to 0.94 in 2023, then fell by 3.59% to 0.91 in 2024, then increased by 1.44% to 0.92 in 2025.
  • Its Equity Ratio was 0.92 in Q3 2025, compared to 0.93 in Q2 2025 and 0.93 in Q1 2025.